Lv22
120 积分 2023-11-16 加入
Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody-Drug Conjugate Payloads
3天前
已完结
ADXd/TLR7-AgonistDual-ConjugateAnti-HER2ADCExertsRobustAntitumorActivityThroughTumorCellKillingandImmuneActivation
3天前
已完结
Neutrophils in cancer: heterogeneous and multifaceted
30天前
已完结
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
1年前
已完结
皖公网安备34019202002308
